Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.

Details

Serval ID
serval:BIB_E3182B041A34
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
Journal
The British journal of dermatology
Author(s)
Maul J.T., Augustin M., Sorbe C., Conrad C., Anzengruber F., Mrowietz U., Reich K., French L.E., Radtke M., Häusermann P., Maul L.V., Boehncke W.H., Thaçi D., Navarini A.A.
ISSN
1365-2133 (Electronic)
ISSN-L
0007-0963
Publication state
Published
Issued date
12/2021
Peer-reviewed
Oui
Volume
185
Number
6
Pages
1160-1168
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Few systematic data on sex-related treatment responses exist for psoriasis.
To evaluate sex differences with respect to systemic antipsoriatic treatment.
Data from patients with moderate-to-severe psoriasis in the PsoBest or Swiss Dermatology Network of Targeted Therapies (SDNTT) registries were analysed. Treatment response was defined as achieving a ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) or PASI ≤ 3 at treatment months 3, 6 and 12, supplemented by patient-reported outcomes [i.e. Dermatology Life Quality Index (DLQI) ≤ 1 and delta DLQI ≥ 4].
In total, 5346 patients registered between 2007 and 2016 were included (PsoBest, n = 4896; SDNTT, n = 450). The majority received nonbiological treatment (67·3% male, 69·8% female). Women showed slightly higher PASI response rates after 3 (54·8% vs. 47·2%; P ≤ 0·001), 6 (70·8% vs. 63·8%; P ≤ 0·001) and 12 months (72·3% vs. 66·1%; P ≤ 0·004). A significantly higher proportion of women achieved a reduction in DLQI ≥ 4 [month 3: 61·4% vs 54·8% (P ≤ 0·001); month 6: 69·6% vs. 62·4% (P ≤ 0·001); month 12: 70·7% vs. 64·4% (P ≤ 0·002)]. Regarding PASI ≤ 3, women on biologics showed a significantly superior treatment response compared with men at 3 (57·8% vs. 48·5%; P ≤ 0·004) and 6 months (69·2% vs. 60·9%; P ≤ 0·018). Women in the nonbiological treatment group had a significantly better treatment response (PASI response, PASI 75 and PASI ≤ 3) over 12 months compared with men.
We provide evidence that women experience better treatment outcomes with systemic antipsoriatic therapy than men.
Keywords
Dermatologic Agents/therapeutic use, Female, Humans, Male, Prospective Studies, Psoriasis/drug therapy, Quality of Life, Registries, Severity of Illness Index, Treatment Outcome
Pubmed
Web of science
Create date
04/05/2021 8:15
Last modification date
10/02/2024 7:16
Usage data